Retinal artery occlusion – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:21 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Retinal artery occlusion – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study comparing tenecteplase and acetylsalicylic acid in patients with central retinal artery occlusion within 4. https://clinicaltrials.eu/trial/study-on-tenecteplase-and-acetylsalicylic-acid-for-patients-with-central-retinal-artery-occlusion/ Wed, 29 Apr 2026 14:58:25 +0000 https://clinicaltrials.eu/trial/study-on-tenecteplase-and-acetylsalicylic-acid-for-patients-with-central-retinal-artery-occlusion/ This study focuses on central retinal artery occlusion, a condition where blood flow to the eye’s retina becomes blocked, which can cause sudden vision loss. The research compares two different treatments: tenecteplase, a medication given through an intravenous injection, and acetylsalicylic acid (also known as aspirin), which is taken as a tablet.

The purpose of this research is to evaluate how effective tenecteplase is when given within 4.5 hours after the first symptoms of central retinal artery occlusion appear. During the study, participants will receive either tenecteplase with a placebo tablet or acetylsalicylic acid with a placebo injection. Neither the patients nor the doctors will know which treatment each participant receives during the study.

The study will monitor changes in vision over time, particularly focusing on vision improvement after 30 days of treatment. Participants will receive either a single dose of tenecteplase through an intravenous injection or acetylsalicylic acid tablets. Some participants will also receive sodium chloride solution (normal saline) as part of their treatment.

]]> Study on Alteplase for Vision Recovery in Patients with Acute Central Retinal Artery Occlusion https://clinicaltrials.eu/trial/study-on-alteplase-for-vision-recovery-in-patients-with-acute-central-retinal-artery-occlusion/ Wed, 29 Apr 2026 14:26:29 +0000 https://clinicaltrials.eu/trial/study-on-alteplase-for-vision-recovery-in-patients-with-acute-central-retinal-artery-occlusion/ This clinical trial is focused on studying a condition called Acute Central Retinal Artery Occlusion (CRAO), which is a sudden blockage of blood flow to the main artery of the eye, leading to a quick and painless loss of vision in one eye. The study is testing a treatment called Alteplase, which is a medication that helps dissolve blood clots. The trial will compare the effects of Alteplase with a placebo to see if it can help improve vision in people who have experienced this type of eye blockage.

The purpose of the study is to see if early treatment with Alteplase can help recover vision in patients with Acute Central Retinal Artery Occlusion. Participants in the study will receive either the Alteplase treatment or a placebo. The study will monitor the participants’ vision over a period of time to assess any improvements. The main goal is to achieve a level of vision that is considered normal to mild impairment, as defined by the World Health Organization.

Throughout the study, participants will have their vision checked at different times to see how well they are recovering. The study will also look at other aspects of eye health and vision quality. The trial aims to provide valuable information on whether Alteplase can be an effective treatment for improving vision in patients with this sudden eye condition.

]]>